Acrobiosystems Co

Acrobiosystems Co EBIT Margin

The EBIT Margin (Operating Margin) of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 23.50 %. In the previous year, EBIT Margin (Operating Margin) was 16.95 % — a change of 38.66% (higher).

EBIT Margin

23.50 %

YoY

38.66%

Last updated:

EBIT Margin (Operating Margin) of Acrobiosystems Co is 2025 23.50 % . EBIT Margin (Operating Margin) of Acrobiosystems Co was 2024 16.95 % . It decreases by 38.66% higher compared to the previous year.

Acrobiosystems Co's operating (EBIT) margin stands at 23.5%, down from 51.0% several years earlier.

The Acrobiosystems Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
14.59 CNY
Jan 1, 2019
14.76 CNY
Jan 1, 2020
56.83 CNY
Jan 1, 2021
50.99 CNY
Jan 1, 2022
34.91 CNY
Jan 1, 2023
24.36 CNY
Jan 1, 2024
16.95 CNY
Jan 1, 2025
23.50 CNY
The Acrobiosystems Co EBIT Margin history
YEAREBIT MarginYoY
23.50 %+38.66%
16.95 %-30.42%
24.36 %-30.23%
34.91 %-31.54%
50.99 %-10.27%
56.83 %+285.08%
14.76 %+1.17%
14.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

EBIT Margin (Operating Margin) of Acrobiosystems Co is 23.50 % in 2025.

EBIT Margin (Operating Margin) of Acrobiosystems Co changed from 16.95 % to 23.50 %, representing a 38.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co